Goldman Sachs upgrades BioNTech to Buy, highlighting the potential of its cancer drug BNT327 and forecasting strong future ...

Summit Therapeutics (NASDAQ: SMMT) is a biotech stock that few investors have heard of, but it has the makings of a winner ...

While it remains to be seen how Summit's oncology turn ultimately shakes out, at this point it is indeed looking like a ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

Akeso begins patient enrollment in phase 3 trial of ivonescimab combination as first-line therapy for biliary tract tumours, compared to durvalumab: China Monday, November 4, 2024 ...

The latest update is out from Summit Therapeutics ( (SMMT) ).

The stock has risen over 600% since the end of 2023, thanks to surprisingly positive trial results for a cancer therapy ...

Aumolertinib showed improved PFS in NSCLC and ivonescimab outperforms pembrolizumab in advanced cases. Plus, insights into CAR T-cell therapy and its associated AEs are discussed in relapsed multiple ...

Quarterly Cash Burn: Below $35 million for operating activities. Summit Therapeutics Inc (NASDAQ:SMMT) has made significant ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.